Avtor/Urednik		Zavratnik, Andrej
Naslov		Pomen hipolipemičnega zdravljenja pri bolnikih z metaboličnim sindromom
Tip		članek
Vir		In: Hojs R, Krajnc I, Pahor A, et al, editors. Zbornik predavanj in praktikum 19. srečanje internistov in zdravnikov splošne medicine "Iz prakse za prakso"; 2008 maj 30-31; Maribor. Maribor: Univerzitetni klinični center,
Leto izdaje		2008
Obseg		str. 21-9
Jezik		slo
Abstrakt		The condition known as the metabolic syndrome (MetS) has become a growing public health concern because of its increasing prevalence and its association with an increased risk of cardiovascular disease and type 2 diabetes mellitus. Dyslipidemia is an important factor in cardiovascular risk in these patients, and treatment of it has been identified as an important goal of therapy in patients with MetS. Among lipid abnormalities LDL cholesterol is the primary target of therapy in MetS, and the non-HDL cholesterol becomes the next target of treatment after the LDL cholesterol goal is reached.
Izvleček		Metabolični sindrom (MetS) velja za naraščajoč zdravstveni problem, saj je povezan z zvečanim tveganjem za nastanek bolezni srca in ožilja (BSO) in tipa 2 sladkorne bolezni (SB2), njegova prevalenca pa narašča. Med nenormalnostmi velja dislipidemija pri osebah z MetS za pomemben terapevtski cilj. Primarni cilj ukrepov je usmerjen k zniževanju LDL holesterola, po tem ko zanj dosežemo ciljne meje pa postane naslednja tarča ukrepov ne-HDL holesterol.
Deskriptorji		CARDIOVASCULAR DISEASES